Download PDF
Der Klinikarzt 2018; 47(10): 484-487
DOI: 10.1055/a-0751-0682
Serie
© Georg Thieme Verlag Stuttgart · New York

„Standard Changing News Onkologie“ in der Tumorchirurgie

Konzepte beim Ösophagus-, Magen- und Pankreaskarzinom sowie bei Neuroendokrinen Tumoren (NET); „Hot topic“ Peritonealkarzinose
Alfred Königsrainer
Universitätsklinik für Allgemeine, Viszeral- und Transplantationschirurgie Tübingen, Tübingen
› Author Affiliations
Further Information

Publication History

Publication Date:
31 October 2018 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Tumorerkrankungen stellen nach wir vor die zweithäufigste krankheitsbedingte Todesursache in der westlichen Welt dar. Trotz aller Fortschritte in der Diagnostik, der medikamentösen Tumortherapie aber auch in der chirurgischen Onkologie verlieren wir nach wie vor ca. 50 % der Patienten am Tumorleiden. Schonende Chirurgie durch minimal invasives Operieren auf der einen Seite erlaubt vielfach eine raschere Rekonvaleszenz bei gleicher onkologischer Qualität, und maximale Chirurgie bei metastasierten Erkrankungen auf der anderen Seite kann die Prognose auch im Stadium IV deutlich verbessern. Vermehrt kommen auch sogenannte „wait and see“-Strategien zum Einsatz. In diesem Übersichtsbeitrag werden Konzepte beim Ösophaguskarzinom, beim Magenkarzinom, bei Neuroendokrinen Tumoren (NET) und beim Pankreaskarzinom beschrieben. Zuletzt noch „Neues“ zur Peritonealkarzinose bei Darmtumoren vom ASCO 2018.

 

  • Literatur

  • 1 Markar S, Gronnier C, Duhamel A. et al. Salvage Surgery After Chemoradiotherapy in the Management of Esophageal Cancer: Is It a Viable Therapeutic Option?. J Clin Oncol 2015; 33: 3866-3873
    CrossrefPubMedGoogle Scholar
  • 2 van Hagen P 1, Hulshof MC, van Lanschot JJ. et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074-2084
    CrossrefPubMedGoogle Scholar
  • 3 Sakanaka K, Ishida Y, Fujii K. et al. Long-term outcome of definitive radiotherapy for cervical esophageal squamous cell carcinoma. Radiat Oncol 2018; 13: 7
    CrossrefPubMedGoogle Scholar
  • 4 Piessen G, Messager M, Mirabel X. et al. Is there a role for surgery for patients with a complete clinical response after chemoradiation for esophageal cancer? An intention-to-treat case-control study. Ann Surg 2013; 258: 793-799
    CrossrefPubMedGoogle Scholar
  • 5 Castoro C, Scarpa M, Cagol M. et al. Complete clinical response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic oesophagus: is surgery always necessary?. J Gastrointest Surg 2013; 17: 1375-1381
    CrossrefPubMedGoogle Scholar
  • 6 Swisher SG, Moughan J, Komaki RU. et al. Final Results of NRG Oncology RTOG 0246: An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation. J Thorac Oncol 2017; 12: 368-374
    CrossrefPubMedGoogle Scholar
  • 7 Berlth F, Yang HK. Minimal-invasive gastrectomy: what the west can learn from the east?. Updates Surg. 18.06.2018 DOI: doi: 10.1007/s13304–018–0547-z [Epub ahead of print]
    CrossrefPubMedGoogle Scholar
  • 8 Kim W, Kim HH, Han SU. et al. Decreased Morbidity of Laparoscopic Distal Gastrectomy Compared With Open Distal Gastrectomy for Stage I Gastric Cancer: Short-term Outcomes From a Multicenter Randomized Controlled Trial (KLASS-01). Ann Surg 2016; 263: 28-35
    CrossrefPubMedGoogle Scholar
  • 9 Lee HJ, Moon JY, Baek SW. Is Treatment-Emergent Toxicity a Biomarker of Efficacy of Apatinib in Gastric Cancer?. J Clin Oncol 2016; 34: 3823
    PubMedGoogle Scholar
  • 10 Kim HI, Han SU, Yang HK. Multicenter Prospective Comparative Study of Robotic Versus Laparoscopic Gastrectomy for Gastric Adenocarcinoma. Ann Surg 2016; 263: 103-109
    CrossrefPubMedGoogle Scholar
  • 11 Berlth F, Yang HK. Minimal-invasive gastrectomy: what the west can learn from the east?. Updates Surg. 18.06.2018 DOI: doi: 10.1007/s13304–018–0547-z [Epub ahead of print]
    CrossrefPubMedGoogle Scholar
  • 12 Weber F, Dralle H. Surgical aspects of neuroendocrine tumors of the small intestine. Chirurg 2018; 89: 428-433
    CrossrefPubMedGoogle Scholar
  • 13 Capurso G, Rinzivillo M, Bettini R. et al. Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases. Br J Surg 2012; 99: 1480-1486
    CrossrefPubMedGoogle Scholar
  • 14 Blažević A, Zandee WT, Franssen GJH. et al. Mesenteric fibrosis and palliative surgery in small intestinal neuroendocrine tumours. Endocr Relat Cancer 2018; 25: 245-254
    CrossrefPubMedGoogle Scholar
  • 15 Watzka FM, Fottner C, Miederer M. Surgical Treatment of NEN of Small Bowel: A Retrospective Analysis. World J Surg 2016; 40: 749-758
    CrossrefPubMedGoogle Scholar
  • 16 Ethun CG, Postlewait LM, Baptiste GG. Small bowel neuroendocrine tumors: A critical analysis of diagnostic work-up and operative approach. J Surg Oncol 2016; 114: 671-676
    CrossrefPubMedGoogle Scholar
  • 17 Holzer K. [Surgical strategies for small sporadic neuroendocrine pancreatic tumors]. Chirurg 2018; 89: 422-427
    CrossrefPubMedGoogle Scholar
  • 18 Garrido-Laguna I, Hidalgo M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol 2015; 12: 319-3134
    CrossrefPubMedGoogle Scholar
  • 19 Quante AS, Ming C, Rottmann M. et al. Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030. Cancer Med 2016; 5: 2649-2656
    CrossrefPubMedGoogle Scholar
  • 20 Bailey P, Chang DK, Nones K. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 2016; 531: 47-52
    CrossrefPubMedGoogle Scholar
  • 21 Tang K, Lu W, Qin W. et al. Neoadjuvant therapy for patients with borderline resectable pancreatic cancer: A systematic review and meta-analysis of response and resection percentages. Pancreatology 2016; 16: 28-37
    CrossrefPubMedGoogle Scholar
  • 22 Quenet F, Elias D, Roca L. et al. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. (ASCO 2018, Abstract Nr. LBA 3503).
    PubMedGoogle Scholar
  • 23 Löffler M, Schuster H, Zeck A. et al. Pharmacodynamics of Oxaliplatin-Derived Platinum Compounds During Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Emerging Aspect Supporting the Rational Design of Treatment Protocols Ann Surg Oncol. 2017
    PubMedGoogle Scholar
  • 24 van Driel WJ, Koole SN, Sikorska K. et al. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. N Engl J Med 2018; 378: 230-240
    CrossrefPubMedGoogle Scholar